Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs Eli Lilly And Co — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.03 (market cap $378.77M), while Eli Lilly And Co trades at $1,179.27 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 2745.7× JPMorgan Diversified Return International Eqty ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while JPMorgan Diversified Return International Eqty ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Diversified Return International Eqty ETF for 120 Days and Eli Lilly And Co for 93 Days on average.
| JPIN | LLY | |
|---|---|---|
Market Cap | $378.77M | $1.04T |
Volume | 13,861 | 3,064,878 |
52-Week High | $77.80 | $1.28K |
52-Week Low | $64.96 | $799.57 |
Typical Hold Time | 120 Days | 93 Days |
Sector | — | Health |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN trades at $72.875, down 0.09% with bearish technical signals dominating. The ETF shows oversold conditions with RSI readings below 25, while moving averages and oscillators indicate strong selling pressure. Recent analysis highlights JPIN's focus on international value stocks through a smart beta approach.
The ETF faces significant technical headwinds despite oversold conditions. Investors should weigh the bearish momentum against potential value opportunities in international markets, with the upcoming dividend payment in September 2026 providing income consideration.
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
